Emyria Limited EMD.AX · Stock Open Emyria Limited in new tab
Emyria Limited Analysis (EMD.AX)
Is Emyria Limited a good investment? Emyria Limited (EMD.AX) is currently trading at 0.0410 AUD.
Earnings Schedule: Emyria Limited is expected to release its next earnings report on March 4, 2027.
Investor FAQ
Does Emyria Limited pay a dividend?
No, it does not currently pay a dividend.
What asset class is Emyria Limited?
Emyria Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of -0.01.
Company Profile
Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the expand Emyria's MDMA analogue drug development program. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Subiaco, Australia.
Community Discussion